How long you can survive with immunotherapy depends on your overall health, the stage and type of lung cancer, and your age.
In a 2020 study published in the Journal of Clinical Oncology, patients with advanced NSCLC who received pembrolizumab lived for 16.9 months on average.
Talk to your doctor to learn how immunotherapy for lung cancer can help you live longer.